Epstein-Barr virus-specific T-cell receptor (EBV-TCR) (EBV-TCR)

The Epstein-Barr virus-specific T-cell receptor (EBV-TCR) is a specialized protein complex found on the surface of cytotoxic T lymphocytes (CTLs) that specifically recognizes and binds to EBV-derived antigenic peptides presented by Human Leukocyte Antigen (HLA) class I molecules (PubMed: 25603314). These receptors are the primary mediators of the cellular immune response against EBV-infected cells, which are implicated in various diseases including infectious mononucleosis and several types of cancer (PubMed: 19706886). In the context of adoptive immunotherapy, EBV-TCRs are utilized by donor-derived T cells or engineered into a patient's own T cells to target EBV-positive malignancies like post-transplant lymphoproliferative disorder (PTLD) (PubMed: 31534003). The interaction between the EBV-TCR and the peptide-HLA complex on target cells, such as those in a lymphoblastoid cell line, triggers a signaling cascade that leads to T-cell activation and the release of cytotoxic molecules like perforin and granzymes (UniProt: P01848). This targeted mechanism allows for the selective elimination of EBV-infected cells while minimizing damage to healthy, non-infected tissues (EMA: Ebvallo Assessment Report). Therapeutic products like tabelecleucel consist of allogeneic T cells characterized by their specific EBV-TCR expression, providing an "off-the-shelf" treatment option for patients with EBV-associated diseases (PubMed: 28935437). Clinical efficacy of these therapies is often monitored through biomarkers such as EBV DNA viral load and the frequency of EBV-specific T cells in the peripheral blood (PubMed: 25603314). Safety considerations for therapies involving these TCRs include the risk of graft-versus-host disease (GvHD) and potential off-target reactivity if the TCR recognizes similar self-peptides (PubMed: 31534003).

Other names

EBV-specific TCREpstein-Barr virus-specific T-cell receptorTCR recognizing EBV-HLA complexesEBV-CTL receptorEBV-specific T-cell receptor

The EBV-TCR recognizes specific EBV-derived peptides (e.g., from EBNA or LMP proteins) presented by HLA class I molecules on the surface of EBV-infected cells (PubMed: 25603314). This binding activates the T cell, leading to the release of perforin and granzymes, which induce apoptosis in the target cell, and the secretion of cytokines like IFN-gamma to enhance the immune response (UniProt: P01848).